Highlights BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Delayed Toronto S.E. Other stock markets 07:11:20 21/05/2024 pm IST			5-day change	1st Jan Change
2.1 ^CAD	+12.30%		-26.57%	-73.08%

20/05	Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing	MT
15/05	BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	15/05	MT
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting	24/04	MT
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	10/04	CI
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR	09/04	MT
BriaCell Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	19/03	CI
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	07/02	CI
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing	06/02	CI
BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	28/12	CI
BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset	20/12	CI
BriaCell Therapeutics Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	15/12	CI
BriaCell Highlights Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at Breast Cancer Symposium	06/12	MT
BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS	06/12	CI
BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen	30/11	CI
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS? IND	03/11	CI
BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2023	26/23/26	CI
BriaCell Collaborates With New York Cancer & Blood Specialists for Late-Stage Study of Bria-IMT in Advanced Breast Cancer	04/23/04	MT
BriaCell Therapeutics Corp. Initiates Pivotal Phase 3 Study of Bria-Imt? in Advanced Metastatic Breast Cancer	03/23/03	CI
BriaCell Therapeutics Corp. Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer	08/23/08	CI
Spin off	05/23/05	FA
Briacell Therapeutics Corp. Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate A Clinical Trial of Bria-Imt in High-Risk Early-Stage Triple Negative Breast Cancer	31/23/31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Highlights

Filters